DIA, in collaboration with FDA, will host Oligonucleotide-based Therapeutics 2012: Leveraging Regulatory and Industry Knowledge for Future Advancements from April 16-18 in Washington, DC. This conference will bring the latest innovations on oligonucleotide-based therapeutic products to industry professionals.
Session topics will include:
Chemistry, Manufacturing, and Controls (CMC)
“DIA and FDA have collaborated on bringing advancements in oligonucleotide-based therapeutic product development to industry professionals,” says Scientific Advisory Committee Member Cindy Berman, PhD. “Informing, educating, and sharing the latest topics will assist industry professionals in staying at the forefront of oligonucleotide-based knowledge. We aim to support drug development and clinical advances in therapeutic targets, trial design, and safety.”
Register for Oligonucleotide-based Therapeutics 2012.
ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.